{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-031670","form_type":"8-K","ticker":"RNXT","cik":"0001574094","company_name":"RenovoRx, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.231329+00:00","generated_at":"2026-06-21T20:09:38.759765+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"RenovoRx reports Q3 net loss of $2.1M; cash at $8.1M; Phase III interim analysis expected Q4 2022","bullets":["Net loss of $2.1 million for Q3 2022, up from $1.5 million in Q3 2021.","Cash and short-term marketable securities of $8.1 million as of Sep 30, 2022; 9.07M shares outstanding.","G&A expenses rose to $1.3M from $0.6M, driven by post-IPO support and D&O insurance premiums.","Expects first prospective interim analysis of Phase III TIGeR-PaC trial in pancreatic cancer in Q4 2022.","Plans to launch Phase II/III trial in extrahepatic cholangiocarcinoma in Q4 2022/Q1 2023; appointed Angela Gill Nelms as COO."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-031670","json":"https://secwatch.observer/filing/0001493152-22-031670.json","markdown":"https://secwatch.observer/filing/0001493152-22-031670.md","text":"https://secwatch.observer/filing/0001493152-22-031670.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574094/000149315222031670/0001493152-22-031670-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574094/000149315222031670/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:09:38.759765+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7d053077736ee661b97ab7048903625cedc5cf2d","claim":"RenovoRx, Inc. reported the quarter ended September 30, 2022 results: net income $2.1 million.","evidence_excerpt":"Net loss was $2.1 million for the quarter ended on September 30, 2022, compared to a net loss of $1.5 million for Q3 ended September 30, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1574094/000149315222031670/0001493152-22-031670-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Net income","value":"$2.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}